PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

| SUBMISSION TYPE: | | | NEW ASSIGNMENT | | |
|-----------------------|-----------------|----------------------|----------------------|----------------|---|
| NATURE OF CONVE | YANCE: | | SECURITY AGREEMENT | | |
| CONVEYING PARTY | ' DATA | | | | |
| | | N | lame | Execution Date | |
| Three Rivers Pharam | nceuticals, LLC | | | 07/12/2010 | |
| Three Rivers Pharma | aceuticals, LLC | | | 07/12/2010 | |
| Name: | SunTrust Bank | k, as A | Administrative Agent | | |
| | 7 | | | | 1 |
| Street Address: | | 303 Peachtree Street | | | |
| Internal Address: | 23rd Floor | | | | |
| City: | Atlanta | | | | |
| State/Country: | GEORGIA | | | | |
| Postal Code: | 30308 | | | | |
| PROPERTY NUMBE | | | Number | | |
| | | 6720000 | | | |
| | | | | | |
| | | 7723310 | | | |
| Application Number: | | 12180 | 2180139 | | |
| Application Number: 1 | | 12761 | 761869 | | |
| Patent Number: | | | 94 | | |

| Property Type | Number |
|---------------------|----------|
| Patent Number: | 6720000 |
| Patent Number: | 7723310 |
| Application Number: | 12180139 |
| Application Number: | 12761869 |
| Patent Number: | 7538094 |

CORRESPONDENCE DATA

| Fax Number: | (404)572-5128 | | | | |
|---------------------------------------------------------------------------|------------------------|--|--|--|--|
| Correspondence will be sent via US Mail when the fax attempt is unsuccess | | | | | |
| Phone: | 404-572-3458 | | | | |
| Email: | slake@kslaw.com | | | | |
| Correspondent Name: | Susan Lake, Paralegal | | | | |
| Address Line 1: | 1180 Peachtree Street | | | | |
| Address Line 2: | King & Spalding LLP | | | | |
| Address Line 4: | Atlanta, GEORGIA 30309 | | | | |

PATENT REEL: 024678 FRAME: 0603

501231915

| ATTORNEY DOCKET NUMBER: | 52990-015860 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| NAME OF SUBMITTER: | Susan Lake |
| Total Attachments: 9 source=Three Rivers PSA#page1.tif source=Three Rivers PSA#page2.tif source=Three Rivers PSA#page3.tif source=Three Rivers PSA#page4.tif | |
| source=Three Rivers PSA#page5.tif source=Three Rivers PSA#page6.tif source=Three Rivers PSA#page7.tif source=Three Rivers PSA#page8.tif source=Three Rivers PSA#page9.tif | |

Patent Security Agreement

THIS PATENT SECURITY AGREEMENT, dated as of July 12, 2010, is made by the entity identified on the signature page hereto as the Grantor (the "<u>Grantor</u>"), in favor of SunTrust Bank, as administrative agent (in such capacity, together with its successors and permitted assigns, the "<u>Administrative Agent</u>") for the Secured Parties and for the banks and other financial institutions (the "<u>Lenders</u>") from time to time parties to the Revolving Credit and Term Loan Agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "<u>Credit Agreement</u>"), among Three Rivers Pharmaceuticals, LLC (the "<u>Borrower</u>"), 3RP Holding Company, LLC, a Delaware limited liability company ("<u>Holdings</u>"), the lenders from time to time parties thereto, and the Administrative Agent.

WITNESSETH:

WHEREAS, pursuant to the Credit Agreement, the Lenders have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, the Grantor has agreed, pursuant to a Guaranty and Security Agreement of even date herewith in favor of the Administrative Agent (the "<u>Guaranty and Security</u> <u>Agreement</u>"), to guarantee the Obligations (as defined in the Credit Agreement) of the Borrower; and

WHEREAS, the Grantor is party to the Guaranty and Security Agreement pursuant to which the Grantor is required to execute and deliver this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Lenders and the Administrative Agent to enter into the Credit Agreement and to induce the Lenders to make their respective extensions of credit to the Borrower thereunder, the Grantor hereby agrees with the Administrative Agent as follows:

Section 1. <u>Defined Terms</u>. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

<u>Section 2.</u> <u>Grant of Security Interest in Patent Collateral</u>. The Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations of the Grantor, hereby mortgages, pledges and hypothecates to the Administrative Agent for the benefit of the Secured Parties, and grants to the Administrative Agent for the benefit of the Secured Parties a lien on and security interest in, all of its right, title and interest in, to and under the following Collateral (the <u>Patent Collateral</u>"):

(i) all of its Patents and all Patent Licenses providing for the grant by or to the Grantor of any right under any Patent, including, without limitation, those referred to on <u>Schedule 1</u> hereto;

(ii) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing; and

(iii) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

<u>Section 3.</u> <u>Guaranty and Security Agreement</u>. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Guaranty and Security Agreement, and the Grantor hereby acknowledges and agrees that the rights and remedies of the Administrative Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

<u>Section 4.</u> <u>Grantor Remains Liable</u>. The Grantor hereby agrees that, anything herein to the contrary notwithstanding, the Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with its Patents and Patents Licenses subject to a security interest hereunder.

<u>Section 5.</u> <u>Counterparts</u>. This Patent Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

<u>Section 6.</u> <u>Governing Law</u>. This Patent Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

THREE RIVERS PHARMACEUTICALS, LLC as Grantor

By: Name: Title:

Paul F. Fagan, J.D., CPA Executive Vice President/General Counsel

ACCEPTED AND AGREED as of the date first above written:

SUNTRUST BANK as Administrative Agent

By:

Name: Title:

[SIGNATURE PAGE TO PATENT SECURITY AGREEMENT]

IN WITNESS WHEREOF, the Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

٤

Very truly yours,

THREE RIVERS PHARMACEUTICALS, LLC as Grantor

| By: | |
|--------|--|
| Name: | |
| Title: | |

ACCEPTED AND AGREED as of the date first above written:

SUNTRUST BANK as Administrative Agent

By:

Name: John Cappellari Title: Vice President

[SIGNATURE PAGE TO PATENT SECURITY AGREEMENT]

ACKNOWLEDGMENT OF GRANTOR

State of <u>Pennsylvania</u>) County of <u>Allegheny</u>) SS.

On this 2 day of July, 2010 before me personally appeared Paul Fagan, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of Three Rivers Pharmaceuticals, LLC, who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Managers and that he acknowledged said instrument to be the free act and deed of said corporation.

nes Notary Public COMMONWEALTH OF PENNSYLVANIA Notarial Seal Michelle L. Jones, Notary Public Marshall Twp., Allegheny County My Commission Expires May 30, 2012 Member, Pennsylvania Association of Notaries

[ACKNOWLEDGEMENT OF GRANTOR FOR PATENT SECURITY AGREEMENT]

SCHEDULE I TO PATENT SECURITY AGREEMENT

1) Patents

| PATENT | OWNER | SERIAL/ REGISTRATION NO. | FILING/ REGISTRATION DATE |
|--------------------------------------------------------|--------------------------------------|-----------------------------------------------------------------|---------------------------------|
| Process for producing wet ribavirin pellets | Three Rivers Pharmaceuticals, LLC | 6720000 (Publication No. 20030018000) | 04/13/2004 |
| Large dose ribavirin formulations | Three Rivers Pharmaceuticals, LLC | 7723310 (Application No. 11201311) | 04/20/2006 |
| Large dose ribavirin formulations | Three Rivers Pharmaceuticals, LLC | Publication No. 20090012015 (Application No. 12180139) | 01/08/2009 |
| Large dose ribavirin formulations | Three Rivers Pharmaceuticals, LLC | Application No. 12761869 | 04/16/2010 |
| Composition containing ribavirin and use thereof | Three Rivers Pharmaceuticals, LLC | 7538094 (Publication No. 20050019406) | 05/26/2009 |

2) Patent Licenses

| Patent License | Owner | Licensee | Series/Registration No. | Filing/Registration Date |
|-----------------------------------------------------------------|-----------------------------------------------|-----------------------------------------|----------------------------|-----------------------------|
| Preparation of liposome and lipid complex compositions | Regents of the University of California | Three Rivers Pharmaceuticals, LLC | 5,077,057 | 12/31/2001 |
| Preparation of liposome and lipid complex compositions | Regents of the University of California | Three Rivers Pharmaceuticals, LLC | 5,277,914 | 1/11/1994 |
| Preparation of liposome and lipid complex | Regents of the University of California | Three Rivers Pharmaceuticals, LLC | 5,549,910 | 8/27/1996 |

| compositions | | | | |
|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------|-----------|------------|
| Preparation of liposome and lipid complex compositions | Regents of the University of California | Three Rivers Pharmaceuticals, LLC | 5,567,434 | 10/22/1996 |
| Consensus human leukocyte interferon | Amgen, Inc. | Three Rivers Pharmaceuticals, LLC | 4,897,471 | 1/30/1990 |
| Consensus human leukocyte interferon | Amgen, Inc. | Three Rivers Pharmaceuticals, LLC | 5,541,293 | 7/30/1996 |
| Consensus human leukocyte interferon | Amgen, Inc. | Three Rivers Pharmaceuticals, LLC | 5,661,009 | 8/26/1997 |
| N-Terminally chemical modified consensus interferon | Amgen, Inc. | Three Rivers Pharmaceuticals, LLC | 5,824,784 | 10/20/1998 |
| Microbial production of mature human leukocyte | Amgen, Inc. | Three Rivers Pharmaceuticals, LLC | 6,482,613 | 11/19/2002 |
| Consensus human leukocyte interferon | Amgen Inc. | Three Rivers Pharmaceuticals, LLC | 4,695,623 | 09/22/1987 |
| Methods and compositions for the treatment of diseases with consensus interferon while reducing side | Amgen Inc. | Three Rivers Pharmaceuticals, LLC | 5372808 | 12/13/1994 |

| effect | | | | |
|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-----------------------------------------|-----------|------------|
| Use of the human interferon consensus gene for gene therapy | Amgen Inc. | Three Rivers Pharmaceuticals, LLC | 5831062 | 11/03/1998 |
| Methods for retreatment of patients afflicted with hepatitis c using consensus interferon | Amgen Inc. | Three Rivers Pharmaceuticals, LLC | 5,980,884 | 11/09/1999 |
| N-terminally chemically modified protein compositions and methods | Amgen Inc. | Three Rivers Pharmaceuticals, LLC | 5,985,265 | 11/16/1999 |
| Treatment of multiple sclerosis using consensus interferon and il-1 receptor antagonist | Amgen Inc | Three Rivers Pharmaceuticals, LLC | 6,013,253 | 01/11/2000 |
| Microbial production of mature human leukocyte interferons | Hoffman-La Roche Inc. and Genentech, Inc. | Three Rivers Pharmaceuticals, LLC | 6,610,830 | 08/26/2003 |
| Amphotericin b/cholesterol sulfate composition | Intermune, Inc. | Three Rivers Pharmaceuticals, LLC | 4,822,777 | 04/18/1989 |
| A method for treating fungal infections with amphotericin | Intermune, Inc | Three Rivers Pharmaceuticals, LLC | 5,032,582 | 07/16/1991 |

| b/cholesterol sulfate composition | | | | |
|-----------------------------------------------------------------------|----------------|-----------------------------------------|-----------|------------|
| Amphotericin b/cholesterol sulfate composition and method | Intermune, Inc | Three Rivers Pharmaceuticals, LLC | 5,194,266 | 03/16/1993 |

ATL_IMANAGE-7047372.4

PATENT REEL: 024678 FRAME: 0613

RECORDED: 07/14/2010